You are here

Botanical-derived drug discovery for cancer therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA114876-01A2
Agency Tracking Number: CA114876
Amount: $130,207.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 788136880
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (310) 895-0026
Research Institution

DESCRIPTION (provided by applicant): In a screen for naturally occurring angiogenic inhibitors, we have identified an extract from the plant Livistona chinensis, which has potent anti-angiogenic and anti-tumor activity and is non-toxic in mice. To our know
ledge, ours is the first publication in the English literature on this extract from Livistona chinensis. We hypothesize that the Livistona extract inhibits tumorigenesis and angiogenesis, and that the effects exerted by many one or more active components i
n Livistona chinensis may be critical to the chemopreventive or chemotherapeutic application of this extract. In this innovative research proposal, we will identify the active ingredient(s) in the extract based on the in vitro anti-proliferative and antian
giogenic assays; investigate whether these components have an effect when used in in-vivo testing. Our specific aims for Phase 1 are as follows: Aim 1: To isolate and identify the active component(s) from the plant Livistona chinensis using a variety of ch
emical and analytical techniques, including extraction, chromatographic separation, nuclear magnetic resonance, photo diode array, infrared and high resolution mass spectrometry. Aim 2: To test the effect of cach active component on in vitro breast tumorig
enicity and antiogenesis assays. The active components will be tested in breast tumor xenograft models. Furthermore, we will begin to investigate the mechanism(s) of action exerted by the active compound(s). Considering the observed low toxicity, oral avai
lability, stability, and potent pharmacologic activity in our animal models from the plant extract, we see this research of particular high value in the efforts to develop novel effective therapies against breast cancer, and possibly other solid tumors as

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government